Advertisement

Adult-Onset Still’s Disease

  • Stéphane Mitrovic
  • Eugen Feist
  • Bruno FautrelEmail author
Chapter
Part of the Rare Diseases of the Immune System book series (RDIS)

Abstract

Adult-onset Still’s disease (AoSD) is a rare but clinically well-known, polygenic, systemic autoinflammatory disease. It is typically characterized by four main (cardinal) symptoms: spiking fever ≥39 °C, arthralgia or arthritis, skin rash, and hyperleukocytosis (≥10,000 cells/mm3). However, many other clinical features are possible, and it can appear in all age groups with potentially severe inflammatory onset accompanied by a broad spectrum of disease manifestation and complications. Hence, it remains a diagnostic challenge, and the clinician should first rule out infectious, tumoral, or inflammatory differential diagnoses. Determination of the total and glycosylated ferritin levels, although not pathognomonic, can help in diagnosis. New biomarkers have recently been described, but they need to be validated. The disease evolution of AoSD can be monocyclic, polycyclic, or chronic. In chronic disease, a joint involvement is often predominant, and erosions are noted in one-third of patients. Many progresses have been made in the understanding of the pathogenesis over the last decades. This chapter provides a comprehensive insight into the complex and heterogeneous nature of AoSD describing the identified cytokine signaling pathways and biomarkers. It also discusses the current evidence for the usage of biologics in AoSD to provide guidance for treatment decisions, taking into account both the efficacy and the safety of the different therapeutic options.

Keywords

Adult-onset Still’s disease Autoinflammatory disorder Inflammasome Interleukin 1 Pathogenesis Diagnosis Prognosis Treatment 

Notes

Acknowledgments

Conflicts of Interest:

S.M. has received consultant fees from BMS and Pfizer.

E.F. has received consultant fees from AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Sanofi-Aventis, Swedish Orphan BioVitrum, and UCB, as well as a research grant from BMS, Lilly, Novartis, Pfizer, and Roche.

B.F. has received consultant fees from AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Sanofi-Aventis, Swedish Orphan BIovitrum, and UCB, as well as research grants from AbbVie, Lilly, MSD, and Pfizer.

References

  1. 1.
    Bywaters EG. Still’s disease in the adult. Ann Rheum Dis. 1971;30(2):121–33.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22(5):773–92.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Peckham D, Scambler T, Savic S, McDermott MF. The burgeoning field of innate immune-mediated disease and autoinflammation: innate immune-mediated disease and autoinflammation. J Pathol. 2017;241(2):123–39.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Ohta A, Yamaguchi M, Tsunematsu T, Kasukawa R, Mizushima H, Kashiwagi H, et al. Adult Still’s disease: a multicenter survey of Japanese patients. J Rheumatol. 1990;17(8):1058–63.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult Still’s disease: review of 228 cases from the literature. J Rheumatol. 1987;14(6):1139–46.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13(7):708–22.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93(2):91–9.CrossRefGoogle Scholar
  9. 9.
    Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P, et al. Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54(7):587–90.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Wakai K, Ohta A, Tamakoshi A, Ohno Y, Kawamura T, Aoki R, et al. Estimated prevalence and incidence of adult Still’s disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol. 1997;7(4):221–5.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    van de Putte LB, Wouters JM. Adult-onset Still’s disease. Baillieres Clin Rheumatol. 1991;5(2):263–75.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Ota T, Higashi S, Suzuki H, Eto S. Increased serum ferritin levels in adult Still’s disease. Lancet. 1987;1(8532):562–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Fautrel B, Zing E, Golmard J-L, Le Moel G, Bissery A, Rioux C, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore). 2002;81(3):194–200.CrossRefGoogle Scholar
  14. 14.
    Lebrun D, Mestrallet S, Dehoux M, Golmard JL, Granger B, Georgin-Lavialle S, et al. Validation of the Fautrel classification criteria for adult-onset Still’s disease. Semin Arthritis Rheum. 2018;47(4):578–85.PubMedCrossRefGoogle Scholar
  15. 15.
    Masson C, Le Loët X, Lioté F, Renou P, Dubost JJ, Boissier MC, et al. Adult Still’s disease: Part I. Manifestations and complications in sixty-five cases in France. Rev Rhum Engl Ed. 1995;62(11):748–57.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Feist E, Mitrovic S, Fautrel B. Adult-onset Still’s disease: new mechanisms, biomarkers and targets. Nat Rev Rheumatol. 2018;14(10):603–18.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Crispín JC, Martínez-Baños D, Alcocer-Varela J. Adult-onset Still disease as the cause of fever of unknown origin. Medicine (Baltimore). 2005;84(6):331–7.CrossRefGoogle Scholar
  18. 18.
    Zuelgaray E, Battistella M, Sallé de Chou C, Vignon-Pennamen M-D, Rybojad M, Petit A, et al. Increased severity and epidermal alterations in persistent versus evanescent skin lesions in adult onset Still’s disease. J Am Acad Dermatol. 2018;79(5):969–71.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Nguyen KH, Weisman MH. Severe sore throat as a presenting symptom of adult onset Still’s disease: a case series and review of the literature. J Rheumatol. 1997;24(3):592–7.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Lyberatos C. Two more cases of Still’s disease and Kikuchi’s. J Rheumatol. 1990;17(4):568–9.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Samuels AJ, Berney SN, Tourtellotte CD, Artymyshyn R. Coexistence of adult onset Still’s disease and polymyositis with rhabdomyolysis successfully treated with methotrexate and corticosteroids. J Rheumatol. 1989;16(5):685–7.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Moreno-Alvarez MJ, Citera G, Maldonado-Cocco JA, Taratuto AL. Adult Still’s disease and inflammatory myositis. Clin Exp Rheumatol. 1993;11(6):659–61.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Gonzalez-Hernandez T, Martin-Mola E, Fernandez-Zamorano A, Balsa-Criado A, de Miguel-Mendieta E. Serum ferritin can be useful for diagnosis in adult onset Still’s disease. J Rheumatol. 1989;16(3):412–3.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Akritidis N, Giannakakis I, Giouglis T. Ferritin levels and response to treatment in patients with Adult Still’s disease. J Rheumatol. 1996;23(1):201–2.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Schiller D, Mittermayer H. Hyperferritinemia as a marker of Still’s disease. Clin Infect Dis. 1998;26(2):534–5.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev. 2007;6(7):457–63.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Fautrel B, Le Moël G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol. 2001;28(2):322–9.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Lee MH, Means RT. Extremely elevated serum ferritin levels in a university hospital: associated diseases and clinical significance. Am J Med. 1995;98(6):566–71.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Van Reeth C, Le Moel G, Lasne Y, Revenant MC, Agneray J, Kahn MF, et al. Serum ferritin and isoferritins are tools for diagnosis of active adult Still’s disease. J Rheumatol. 1994;21(5):890–5.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Vignes S, Le Moël G, Fautrel B, Wechsler B, Godeau P, Piette JC. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still’s disease. Ann Rheum Dis. 2000;59(5):347–50.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Lambotte O, Costedoat-Chalumeau N, Amoura Z, Piette JC, Cacoub P. Drug-induced hemophagocytosis. Am J Med. 2002;112(7):592–3.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Lambotte O, Cacoub P, Costedoat N, Le Moel G, Amoura Z, Piette JC. High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol. 2003;30(5):1027–8.PubMedGoogle Scholar
  33. 33.
    Fardet L, Coppo P, Kettaneh A, Dehoux M, Cabane J, Lambotte O. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum. 2008;58(5):1521–7.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    McGonagle D, Savic S, McDermott MF. The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self. Semin Immunopathol. 2007;29(3):303–13.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133–44.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411(6837):599–603.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411(6837):603–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Maria ATJ, Le Quellec A, Jorgensen C, Touitou I, Rivière S, Guilpain P. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13(11):1149–59.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Sève P. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61(1–2):53–62.CrossRefGoogle Scholar
  40. 40.
    Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4(1):34–42.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416–26.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Mitrovic S, Fautrel B. New markers for adult-onset Still’s disease. Joint Bone Spine. 2018;85(3):285–93.PubMedCrossRefGoogle Scholar
  43. 43.
    Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58(12):3924–31.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 2004;50(12):3762–71.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 2004;50(4):1286–95.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still’s disease: a multicentre retrospective observational study. Front Pharmacol [Internet]. 2017 Jun 13 [cited 2018];8. Available from: http://journal.frontiersin.org/article/10.3389/fphar.2017.00369/full.
  47. 47.
    Shields AM, Thompson SJ, Panayi GS, Corrigall VM. Pro-resolution immunological networks: binding immunoglobulin protein and other resolution-associated molecular patterns. Rheumatology (Oxford). 2012;51(5):780–8.CrossRefGoogle Scholar
  48. 48.
    Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92–101.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Hofmann SR, Kubasch AS, Ioannidis C, Rösen-Wolff A, Girschick HJ, Morbach H, et al. Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1β expression and release. Clin Immunol. 2015;161(2):300–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Chen D-Y, Chen Y-M, Lin C-C, Hsieh C-W, Wu Y-C, Hung W-T, et al. The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still’s disease. BMC Musculoskelet Disord. 2015;16:111.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Grateau G, Hentgen V, Stojanovic KS, Jéru I, Amselem S, Steichen O. How should we approach classification of autoinflammatory diseases? Nat Rev Rheumatol. 2013;9(10):624–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Terkeltaub R, Esdaile JM, Décary F, Harth M, Lister J, Lapointe N. HLA-Bw35 and prognosis in adult Still’s disease. Arthritis Rheum. 1981;24(12):1469–72.PubMedCrossRefGoogle Scholar
  53. 53.
    Wouters JM, van de Putte LB. Adult-onset Still’s disease; clinical and laboratory features, treatment and progress of 45 cases. Q J Med. 1986;61(235):1055–65.PubMedGoogle Scholar
  54. 54.
    Wakil SM, Monies DM, Abouelhoda M, Al-Tassan N, Al-Dusery H, Naim EA, et al. Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2015;67(1):288–95.PubMedCrossRefGoogle Scholar
  55. 55.
    Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas J-P, et al. HLA-DRB1∗11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A. 2015;112(52):15970–5.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Aksentijevich I, McDermott MF. Lessons from characterization and treatment of the autoinflammatory syndromes. Curr Opin Rheumatol. 2017;29(2):187–94.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Touitou I. Inheritance of autoinflammatory diseases: shifting paradigms and nomenclature. J Med Genet. 2013;50(6):349–59.PubMedCrossRefGoogle Scholar
  58. 58.
    Sarrabay G, Touitou I. Autoinflammation. Management of hereditary recurrent fevers—SHARE experience. Nat Rev Rheumatol. 2015;11(10):567–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Mitrovic S, Fautrel B. Complications of adult-onset Still’s disease and their management. Expert Rev Clin Immunol. 2018;14(5):351–65.PubMedCrossRefGoogle Scholar
  60. 60.
    Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33(3):305–14.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Colina M, Zucchini W, Ciancio G, Orzincolo C, Trotta F, Govoni M. The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum. 2011;41(2):279–85.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Mimura T, Shimodaira M, Kibata M, Tsukadaira A, Shirahata K. Adult-onset Still’s disease with disseminated intravascular coagulation and hemophagocytic syndrome: a case report. BMC Res Notes. 2014;7:940.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Shinohara T, Hidaka T, Matsuki Y, Suzuki K, Ohsuzu F. Calcinosis cutis and intestinal pseudoobstruction in a patient with adult onset Still’s disease associated with recurrent relapses of disordered coagulopathy. Intern Med. 1999;38(6):516–20.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Yokoyama M, Suwa A, Shinozawa T, Fujii T, Mimori T, Akizuki M, et al. A case of adult onset Still’s disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation. Nihon Rinsho Meneki Gakkai Kaishi. 1995;18(2):207–14.PubMedCrossRefGoogle Scholar
  65. 65.
    Yamashita S, Furukawa NE, Matsunaga T, Hirakawa Y, Tago M, Yamashita S-I. Extremely high serum ferritin: an instrumental marker of masquerading adult-onset Still’s disease with hemophagocytic syndrome. Am J Case Rep. 2017;18:1296–301.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Colina M, Govoni M, Trotta F. Fatal myocarditis in adult-onset still disease with diffuse intravascular coagulation. Rheumatol Int. 2009;29(11):1355–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Namas R, Nannapaneni N, Venkatram M, Altinok G, Levine M, Dhar JP. An unusual case of adult-onset Still’s disease with hemophagocytic syndrome, necrotic leukoencephalopathy and disseminated intravascular coagulation. Case Rep Rheumatol. 2014;2014:128623.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Kötter I, Wacker A, Koch S, Henes J, Richter C, Engel A, et al. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37(3):189–97.PubMedCrossRefGoogle Scholar
  69. 69.
    Hong D, Yang Z, Han S, Liang X, Ma K, Zhang X. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther. 2014;8:2345–57.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Sakata N, Shimizu S, Hirano F, Fushimi K. Epidemiological study of adult-onset Still’s disease using a Japanese administrative database. Rheumatol Int. 2016;36(10):1399–405.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Matsumoto K, Nagashima T, Takatori S, Kawahara Y, Yagi M, Iwamoto M, et al. Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab. Clin Rheumatol. 2009;28(4):485–7.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Park J-H, Bae JH, Choi Y-S, Lee H-S, Jun J-B, Jung S, et al. Adult-onset Still’s disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine A. J Korean Med Sci. 2004;19(1):137–41.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Kumar A, Kato H. Macrophage activation syndrome associated with adult-onset Still’s disease successfully treated with anakinra. Case Rep Rheumatol. 2016;2016:3717392.PubMedPubMedCentralGoogle Scholar
  74. 74.
    El Karoui K, Karras A, Lebrun G, Charles P, Arlet JB, Jacquot C, et al. Thrombotic microangiopathy and purtscher-like retinopathy associated with adult-onset Still’s disease: a role for glomerular vascular endothelial growth factor? Arthritis Rheum. 2009;61(11):1609–13.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103(11):4043–9.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Masuyama A, Kobayashi H, Kobayashi Y, Yokoe I, Sugimura Y, Maniwa K, et al. A case of adult-onset Still’s disease complicated by thrombotic thrombocytopenic purpura with retinal microangiopathy and rapidly fatal cerebral edema. Mod Rheumatol. 2013;23(2):379–85.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Chen CH, Chen HA, Wang HP, Liao HT, Chou CT, Huang DF. Pulmonary arterial hypertension in autoimmune diseases: an analysis of 19 cases from a medical center in northern Taiwan. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi. 2006;39(2):162–8.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Menezes de Siqueira ME, Rodrigues RP, Kormann APM. Adult-onset Still’s disease and pulmonary arterial hypertension. Respir Med CME. 2009;2(2):70–2.CrossRefGoogle Scholar
  79. 79.
    Guilleminault L, Laurent S, Foucher A, Poubeau P, Paganin F. Pulmonary arterial hypertension in adult onset Still’s disease: a case report of a severe complication. BMC Pulm Med. 2016;16(1):72.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Kadavath S, Zapantis E, Zolty R, Efthimiou P. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still’s disease: targeting IL-6. Int J Rheum Dis. 2014;17(3):336–40.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Lowther GH, Chertoff J, Cope J, Alnuaimat H, Ataya A. Pulmonary arterial hypertension and acute respiratory distress syndrome in a patient with adult-onset Still’s disease. Pulm Circ. 2017;7(4):797–802.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Mehta MV, Manson DK, Horn EM, Haythe J. An atypical presentation of adult-onset Still’s disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature. Pulm Circ. 2016;6(1):136–42.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Mubashir E, Ahmed MM, Hayat S, Heldmann M, Berney SM. Pulmonary hypertension in a patient with adult-onset Still’s disease. Clin Rheumatol. 2007;26(8):1359–61.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Padilla-Ibarra J, Sanchez-Ortiz A, Sandoval-Castro C, Ramos-Remus C. Rituximab treatment for pulmonary arterial hypertension in adult-onset Still’s disease. Clin Exp Rheumatol. 2013;31(4):657–8.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Thakare M, Habibi S, Agrawal S, Narsimulu G. Pulmonary arterial hypertension complicating adult-onset Still’s disease. Clin Rheumatol. 2013;32(Suppl 1):S1–2.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Weatherald J, Lategan J, Helmersen D. Pulmonary arterial hypertension secondary to adult-onset Still’s disease: response to cyclosporine and sildenafil over 15 years of follow-up. Respir Med Case Rep. 2016;19:27–30.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Zen A, Yamashita N, Ueda M, Asakawa Y, Yoshikawa Y, Funai T, et al. A case of adult Still’s disease with pulmonary hypertension. Ryumachi. 1990;30(1):45–52.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Campos M, Schiopu E. Pulmonary arterial hypertension in adult-onset Still’s disease: rapid response to anakinra. Case Rep Rheumatol. 2012;2012:537613.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Uppal SS, Al-Mutairi M, Hayat S, Abraham M, Malaviya A. Ten years of clinical experience with adult onset Still’s disease: is the outcome improving? Clin Rheumatol. 2007;26(7):1055–60.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Ben Ghorbel I, Khanfir M, Houman MH. Amyloidosis in adult onset Still’s disease. Rev Med Interne. 2004;25(9):675–7.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Ishii T, Sasaki T, Muryoi T, Murai C, Hatakeyama A, Oosaki H, et al. Systemic amyloidosis in a patient with adult onset Still’s disease. Intern Med. 1993;32(1):50–2.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Oh YB, Bae SC, Jung JH, Kim TH, Jun JB, Jung SS, et al. Secondary renal amyloidosis in adult onset Still’s disease: case report and review of the literature. Korean J Intern Med. 2000;15(2):131–4.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Rivera F, Gil CM, Gil MT, Batlle-Gualda E, Trigueros M, Olivares J. Vascular renal AA amyloidosis in adult Still’s disease. Nephrol Dial Transplant. 1997;12(8):1714–6.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–20.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Drepper M, Rubbia-Brandt L, Spahr L. Tocilizumab-induced acute liver injury in adult onset Still’s disease. Case Rep Hepatol. 2013;2013:964828.Google Scholar
  96. 96.
    Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100(2):710–3.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Hirata S, Okamoto H, Ohta S, Kobashigawa T, Uesato M, Kawaguchi Y, et al. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still’s disease. Rheumatology (Oxford). 2006;45(8):1046–7.CrossRefGoogle Scholar
  98. 98.
    Gopal M, Cohn CD, McEntire MR, Alperin JB. Thrombotic thrombocytopenic purpura and adult onset Still’s disease. Am J Med Sci. 2009;337(5):373–6.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Huertas A, Perros F, Tu L, Cohen-Kaminsky S, Montani D, Dorfmüller P, et al. Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. Circulation. 2014;129(12):1332–40.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250–94.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75.CrossRefGoogle Scholar
  102. 102.
    Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2):118–36.CrossRefGoogle Scholar
  103. 103.
    Reginato AJ, Schumacher HR, Baker DG, O’Connor CR, Ferreiros J. Adult onset Still’s disease: experience in 23 patients and literature review with emphasis on organ failure. Semin Arthritis Rheum. 1987;17(1):39–57.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Boki KA, Tsirantonaki MJ, Markakis K, Moutsopoulos HM. Thrombotic thrombocytopenic purpura in adult Still’s disease. J Rheumatol. 1996;23(2):385–7.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Cabane J, Lebas J, Wattiaux MJ, Imbert JC. Pseudo-Still disease and neoplasm. 2 cases. Rev Med Interne. 1988;9(1):81–4.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Sanmarti R, Cañete JD, Salvador G. Palindromic rheumatism and other relapsing arthritis. Best Pract Res Clin Rheumatol. 2004;18(5):647–61.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore). 1994;73(3):133–44.CrossRefGoogle Scholar
  108. 108.
    Masson C, Simon V, Hoppé E, Insalaco P, Cissé I, Audran M. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS): definition, semiology, prognosis, pathogenesis, treatment, and place relative to other periodic joint diseases. Joint Bone Spine. 2004;71(4):284–90.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3):424–30.Google Scholar
  110. 110.
    Ichida H, Kawaguchi Y, Sugiura T, Takagi K, Katsumata Y, Gono T, et al. Clinical manifestations of adult-onset Still’s disease presenting with erosive arthritis: association with low levels of ferritin and interleukin-18. Arthritis Care Res. 2014;66(4):642–6.CrossRefGoogle Scholar
  111. 111.
    Kim H-A, An J-M, Nam J-Y, Jeon J-Y, Suh C-H. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol. 2012;39(7):1399–406.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Kim HA, Han JH, Kim WJ, Noh HJ, An JM, Yim H, et al. TLR4 endogenous ligand S100A8/A9 levels in adult-onset Still’s disease and their association with disease activity and clinical manifestations. Int J Mol Sci. 2016;17(8)  https://doi.org/10.3390/ijms17081342.PubMedCentralCrossRefGoogle Scholar
  113. 113.
    Scirè CA, Cavagna L, Perotti C, Bruschi E, Caporali R, Montecucco C. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24(2):123–8.PubMedPubMedCentralGoogle Scholar
  114. 114.
    Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum. 2001;44(3):550–60.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Chen D-Y, Lan J-L, Lin F-J, Hsieh T-Y. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol. 2004;31(11):2189–98.Google Scholar
  116. 116.
    Choi J-H, Suh C-H, Lee Y-M, Suh Y-J, Lee S-K, Kim S-S, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30(11):2422–7.PubMedPubMedCentralGoogle Scholar
  117. 117.
    Priori R, Colafrancesco S, Alessandri C, Minniti A, Perricone C, Iaiani G, et al. Interleukin 18: a biomarker for differential diagnosis between adult-onset Still’s disease and sepsis. J Rheumatol. 2014;41(6):1118–23.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Rooney T, Murphy E, Benito M, Roux-Lombard P, FitzGerald O, Dayer J-M, et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis. 2004;63(11):1393–8.PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Conigliaro P, Priori R, Bombardieri M, Alessandri C, Barone F, Pitzalis C, et al. Lymph node IL-18 expression in adult-onset Still’s disease. Ann Rheum Dis. 2009;68(3):442–3.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Priori R, Barone F, Alessandri C, Colafrancesco S, McInnes IB, Pitzalis C, et al. Markedly increased IL-18 liver expression in adult-onset Still’s disease-related hepatitis. Rheumatology (Oxford). 2011;50(4):776–80.CrossRefGoogle Scholar
  121. 121.
    Kawaguchi Y, Terajima H, Harigai M, Hara M, Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still’s disease. Arthritis Rheum. 2001;44(7):1716–7.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Jung K-H, Kim J-J, Lee J-S, Park W, Kim T-H, Jun J-B, et al. Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still’s disease. Scand J Rheumatol. 2014;43(2):162–9.CrossRefGoogle Scholar
  123. 123.
    Sugiura T, Kawaguchi Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T, et al. Association between adult-onset Still’s disease and interleukin-18 gene polymorphisms. Genes Immun. 2002;3(7):394–9.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol. 2010;37(5):967–73.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol. 2010;37(11):2369–76.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Bae C-B, Suh C-H, An J-M, Jung J-Y, Jeon J-Y, Nam J-Y, et al. Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol. 2014;41(12):2403–8.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Han JH, Suh C-H, Jung J-Y, Nam J-Y, Kwon JE, Yim H, et al. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still’s disease. Arthritis Res Ther. 2015;17:260.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(3):965–71.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Colafrancesco S, Priori R, Alessandri C, Astorri E, Perricone C, Blank M, et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res. 2014;60(2–3):177–83.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Zou Y-Q, Lu L-J, Li S-J, Zeng T, Wang X-D, Bao C-D, et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still’s disease. Clin Biochem. 2008;41(7–8):519–24.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Chen D-Y, Lan J-L, Lin F-J, Hsieh T-Y. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still’s disease. Arthritis Rheum. 2005;53(3):320–7.PubMedCrossRefGoogle Scholar
  132. 132.
    Efthimiou P, Kontzias A, Ward CM, Ogden NS. Adult-onset Still’s disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol. 2007;3(6):328–35.PubMedCrossRefGoogle Scholar
  133. 133.
    Masson C, Le Loët X, Lioté F, Renou P, Dubost JJ, Boissier MC, et al. Adult Still’s disease. Part II. Management, outcome, and prognostic factors. Rev Rhum Engl Ed. 1995;62(11):758–65.PubMedGoogle Scholar
  134. 134.
    Medsger TA, Christy WC. Carpal arthritis with ankylosis in late onset Still’s disease. Arthritis Rheum. 1976;19(2):232–42.PubMedCrossRefGoogle Scholar
  135. 135.
    Sampalis JS, Esdaile JM, Medsger TA, Partridge AJ, Yeadon C, Senécal JL, et al. A controlled study of the long-term prognosis of adult Still’s disease. Am J Med. 1995;98(4):384–8.PubMedCrossRefGoogle Scholar
  136. 136.
    Fujii T, Akizuki M, Kameda H, Matsumura M, Hirakata M, Yoshida T, et al. Methotrexate treatment in patients with adult onset Still’s disease—retrospective study of 13 Japanese cases. Ann Rheum Dis. 1997;56(2):144–8.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Aydintug AO, D’Cruz D, Cervera R, Khamashta MA, Hughes GR. Low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1992;19(3):431–5.PubMedGoogle Scholar
  138. 138.
    Fautrel B, Borget C, Rozenberg S, Meyer O, Le Loët X, Masson C, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1999;26(2):373–8.PubMedGoogle Scholar
  139. 139.
    Fitzgerald AA, LeClercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52(6):1794–803.PubMedCrossRefGoogle Scholar
  140. 140.
    Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease. Ann Rheum Dis. 2010;69(2):466–7.PubMedCrossRefGoogle Scholar
  141. 141.
    Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis S-NC. Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66(6):842–3.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2007;67(3):302–8.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, et al. Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res. 2013;65(5):822–6.CrossRefGoogle Scholar
  144. 144.
    Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A, et al. Efficacy of anakinra in refractory adult-onset Stillʼs disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94(39):e1554.CrossRefGoogle Scholar
  145. 145.
    Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum. 2012;42(2):201–5.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Lo Gullo A, Caruso A, Pipitone N, Macchioni P, Pazzola G, Salvarani C. Canakinumab in a case of adult onset Still’s disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014;81(4):376–7.PubMedCrossRefGoogle Scholar
  147. 147.
    Barsotti S, Neri R, Iacopetti V, d’Ascanio A, Talarico R, Tripoli A, et al. Successful treatment of refractory adult-onset still disease with canakinumab: a case report. J Clin Rheumatol. 2014;20(2):121.PubMedCrossRefGoogle Scholar
  148. 148.
    Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis. 2012;71(12):2056–8.PubMedCrossRefGoogle Scholar
  149. 149.
    Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum. 2002;46(5):1171–6.PubMedCrossRefGoogle Scholar
  150. 150.
    Kiyonaga Y, Maeshima K, Imada C, Haranaka M, Ishii K, Shibata H. Steroid-sparing effects of etanercept in a patient with steroid-dependent adult-onset Still’s disease. Intern Med. 2014;53(11):1209–13.PubMedCrossRefGoogle Scholar
  151. 151.
    Kaneko K, Kaburaki M, Muraoka S, Tanaka N, Yamamoto T, Kusunoki Y, et al. Exacerbation of adult-onset Still’s disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration: exacerbation of AOSD after etanercept. Int J Rheum Dis. 2010;13(4):e67–9.PubMedCrossRefGoogle Scholar
  152. 152.
    Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis. 2001;60(Suppl 3):iii55–7.PubMedPubMedCentralGoogle Scholar
  153. 153.
    Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol. 2001;19(3):329–32.PubMedPubMedCentralGoogle Scholar
  154. 154.
    Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64(2):262–6.PubMedCrossRefGoogle Scholar
  155. 155.
    Puéchal X, DeBandt M, Berthelot J-M, Breban M, Dubost J-J, Fain O, et al. Tocilizumab in refractory adult Still’s disease: refractory ASD and tocilizumab. Arthritis Care Res. 2011;63(1):155–9.CrossRefGoogle Scholar
  156. 156.
    Elkayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol. 2014;41(2):244–7.PubMedCrossRefGoogle Scholar
  157. 157.
    Cipriani P, Ruscitti P, Carubbi F, Pantano I, Liakouli V, Berardicurti O, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2014;33(1):49–55.PubMedCrossRefGoogle Scholar
  158. 158.
    Thonhofer R, Hiller M, Just H, Trummer M, Siegel C, Dejaco C. Treatment of refractory adult-onset Still’s disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int. 2011;31(12):1653–6.PubMedCrossRefGoogle Scholar
  159. 159.
    Li T, Gu L, Wang X, Guo L, Shi H, Yang C, et al. A pilot study on tocilizumab for treating refractory adult-onset Still’s disease. Sci Rep [Internet]. 2017. [cited 2018 Feb 4];7(1). Available from: http://www.nature.com/articles/s41598-017-13639-y.
  160. 160.
    Song ST, Kim JJ, Lee S, Kim H-A, Lee EY, Shin KC, et al. Efficacy of tocilizumab therapy in Korean patients with adult-onset Still’s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol. 2016;34(6. Suppl 102):S64–71.PubMedPubMedCentralGoogle Scholar
  161. 161.
    Ma Y, Wu M, Zhang X, Xia Q, Yang J, Xu S, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: a meta-analysis. Mod Rheumatol. 2018;28(5):849–57.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Nishina N, Kaneko Y, Kameda H, Takeuchi T. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: a retrospective, single-center study. Mod Rheumatol. 2015;25(3):401–4.PubMedCrossRefGoogle Scholar
  163. 163.
    Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis. 2018;77(6):840–7.PubMedPubMedCentralGoogle Scholar
  164. 164.
    Belfeki N, Smiti Khanfir M, Said F, Hamzaoui A, Ben Salem T, Ben Ghorbel I, et al. Successful treatment of refractory adult onset Still’s disease with rituximab. Reumatismo. 2016;68(3):159–62.PubMedCrossRefGoogle Scholar
  165. 165.
    Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol. 2011;17(6):315–7.PubMedCrossRefGoogle Scholar
  166. 166.
    Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still’s disease. Clin Exp Rheumatol. 2010;28(2):265–7.PubMedPubMedCentralGoogle Scholar
  167. 167.
  168. 168.
  169. 169.
    Junge G, Mason J, Feist E. Adult onset Still’s disease—the evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum. 2017;47(2):295–302.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Stéphane Mitrovic
    • 1
    • 2
    • 3
  • Eugen Feist
    • 4
  • Bruno Fautrel
    • 1
    • 3
    • 5
    Email author
  1. 1.Department of RheumatologyPitié-Salpêtière Hospital, AP-HPParisFrance
  2. 2.Department of Internal MedicineInstitut Mutualiste MontsourisParisFrance
  3. 3.CEREMAIA, Reference Center for Autoinflammatory Diseases and AmyloidosisParisFrance
  4. 4.Department of Rheumatology and Clinical ImmunologyCharité—UniversitätsmedizinBerlinGermany
  5. 5.Sorbonne Université, Pierre Louis Institute of Epidemiology and Public HealthParisFrance

Personalised recommendations